ArticleRegenerative therapy2026
Monthly multiple injections of leukocyte-poor platelet-rich plasma (ACP®) for knee osteoarthritis: clinical effectiveness across KL grades, dose-response plateau at four, and 24-month durability.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Monthly, ultrasound-guided intra-articular injections of leukocyte-poor platelet-rich plasma (ACP®) are widely used for knee osteoarthritis (KOA), but optimal dosing and cumulative exposure remain unclear. Methods: We retrospectively analyzed prospectively planned ACP treatments at a single clinic. Knees with KL1-4 received fixed per-knee doses (3 mL [3A] or 6 mL [6A]) monthly up to six sessions. Primary outcome was VAS pain; secondary outcomes were KOOS (Pain/ADL/QoL), OMERACT-OARSI response, MOAKS-BML, and joint effusion (JF). ANCOVA for ΔVAS at 12 months adjusted for baseline VAS and prespecified covariates; longitudinal mixed-effects models and segmented regression assessed dose-response and breakpoint. Results: Pain improved at 12 months (n = 115) and was maintained at 24 months (n = 67). Segmented regression identified a dose-response plateau around the 4th injection. The 6 mL regimen showed no robust adjusted advantage over 3 mL at 12 months. KOOS domains and OMERACT-OARSI responder rates improved at 12 months and persisted at 24 months. MOAKS-BML decreased from 12 to 24 months; JF tended to decline. No serious adverse events related to ACP injections were documented. Conclusions: Under a fixed monthly protocol mirroring our LR-PRP schedule, ACP (LP-PRP) produced clinically meaningful improvements across KL1-4 with a practical evaluation horizon through the 4th injection and no clear per-session volume benefit of 6 mL over 3 mL. Prospective randomization of dose within a monthly-multiple framework is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.